2. Protein Tyrosine Kinase/RTK
  3. PDGFR
  4. Olaratumab

Olaratumab  (Synonyms: IMC-3G3; LY3012207)

Cat. No.: HY-P9922 Purity: ≥95.0%
Data Sheet
SDS
COA
Technical Support

Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity.

For research use only. We do not sell to patients.

CAS No. : 1024603-93-7

Size Price Stock Quantity
1 mg USD 300 In-stock
5 mg USD 780 In-stock
10 mg USD 1250 In-stock
50 mg   Get quote  
100 mg   Get quote  

Get it tomorrow April 1 by noon. Order within 8 hrs 44 mins.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Olaratumab Featured Recommendations:

Top Publications Citing Use of Products

View All PDGFR Isoform Specific Products:

View All Isoforms
PDGFR PDGFRβ PDGFRα

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity[1].
Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species

Human
In Vitro

IMC-3G3 (100 μg/mL, 72 h) blocked PDGFRα phosphorylation in SKOV3-ip1 cells. And the combined treatment of IMC-3G3 and docetaxel significantly induced apoptosis in SKOV3-ip1 and HeyA8 cell lines[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo

IMC-3G3 (i.p., 40 mg/kg, three times per week, 6 weeks) in SKOV3-ip1 tumor-bearing mice, compared with the control group, IMC-3G3 treatment alone had no obvious anti-tumor effect, while in HeyA8 tumor-bearing mice, IMC-3G3 monotherapy showed a significant anti-tumor effect compared with the control group, with a tumor reduction rate of 62%[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
NCT NumberSponsorConditionStart DatePhase
NCT03698227Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Advanced Soft Tissue Sarcoma
November 12, 2018Phase 2
NCT02451943Eli Lilly and Company
Soft Tissue Sarcoma
September 14, 2015Phase 3
NCT02677116Eli Lilly and Company
Neoplasm Metastasis
August 29, 2016Phase 1
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Olaratumab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Olaratumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

Olaratumab1024603-93-7IMC-3G3 LY3012207LY3012207LY 3012207LY-3012207PDGFRPlatelet-derived growth factor receptormonoclonal antibodyIgG1antitumorInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Olaratumab
Cat. No.:
HY-P9922
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.